Meta-Analysis
Copyright ©The Author(s) 2017.
World J Gastroenterol. Dec 7, 2017; 23(45): 8082-8089
Published online Dec 7, 2017. doi: 10.3748/wjg.v23.i45.8082
Table 1 Studies included in systematic review
Study IDYrStudy periodType of studySample sizeIBD patients with active diseaseIBD patients with inactive diseaseOutcomes
Disease activity and SGA
Bröms et al[19]20142006-2010R470110988972SGA and LBW
Bush et al[20]20041986-2001R565142294SGA and LBW
de Lima-Karagiannis et al[21]20162008-2014P29892134SGA and LBW
Moser et al[6]20001993-1997R1301352SGA
Stephansson et al[27]20111994-2006R871579No raw data providedSGA
Mahadevan et al[26]2012P797No raw data providedSGA
Disease activity and LBW
Bortlik et al[24]20132007-2012R411031LBW
Bröms et al[19]20142006-2010R470110988972SGA and LBW
Bush et al[20]20041986-2001R565142294SGA and LBW
de Lima-Karagiannis et al[21]20162008-2014P29892134SGA and LBW
Molnár et al[28]2010R167No raw data providedLBW
Bortoli et al[7]20112003-2006P664No raw data providedLBW
Treatment and SGAThiopurine exposureNon thiopurine exposure
Bröms et al[19]20142006-2010R4701104211539SGA and LBW
Cleary BJ(23)20091995-2007R1164030315676SGA and LBW
Treatment and LBW
Bröms et al[19] (AZA)20142006-2010R4701104211539SGA and LBW
Cleary et al[23]20091995-2007R11640303151676SGA and LBW
Komoto et al[25] (AZA)20162008-2014R72729LBW
Nørgård et al[5]20071996-2004R90020628LBW
Shim et al[22]20111996-2006R931974LBW
Nørgård et al[10]20031991-2000R19437No raw data providedLBW
Table 2 Active disease definitions
StudyActive or inactive disease definition
Bröms et al[19]Any change in the treatment
Bush et al[20]Hospitalization
Moser et al[6]Surgery due to a flare of the disease
Shim et al[22]
de Lima-Karagiannis et al[21]HBI > 5
Komoto et al[25]SCCAI > 2; Partial Mayo Score Fecal calprotectin > 200 microgr/gr
Bortlik et al[24]Consideration of treating physician